NIH Research Clears Way for Study of Experimental Treatment for Opioid Use Disorder

Follow Drugslib on

June 1, 2026 -- The National Institutes of Health (NIH) today announced that its Investigational New Drug (IND) application for mitragynine, the primary psychoactive compound found in Mitragyna speciosa (kratom), has taken effect with the U.S. Food and Drug Administration (FDA). The IND paves the way for an NIH-led phase I clinical trial to evaluate mitragynine as a potential treatment for opioid use disorder.

  • IND in effect for human safety study of mitragynine, a kratom isolate.

    • Researchers at NIH and the University of Florida developed the purified formulation of mitragynine to be used in the trial, as well as the preclinical work that led to the submission of the IND application.

    “This IND is a major step toward expanding treatment options for the millions of Americans struggling with opioid use disorder, which has contributed to historically high overdose mortality rates,” said Nora Volkow, M.D., director of NIH’s National Institute on Drug Abuse (NIDA).

    Interest in kratom, a tropical tree found in southeast Asia, as a treatment for opioid use disorder has increased in recent years, with many reportedly using it for opioid withdrawal, pain, and other conditions as well.

    While the kratom plant contains many compounds known to interact with opioid receptors, research indicates that its potential therapeutic effects are likely driven by the slow conversion of mitragynine in the body. Preclinical studies led by scientists at the University of Florida and NIH’s National Center for Advancing Translational Sciences (NCATS) and NIDA have demonstrated that mitragynine administration, across several doses, did not raise significant safety concerns in animal models.

    However, the compound in isolation has yet to be studied in humans. With the IND in effect, investigators can now begin that work.

    NIH scientists are planning to conduct the first randomized, double-blind, placebo-controlled study to assess the safety and tolerability of the mitragynine formulation in humans.

    “We’ve seen the potential of mitragynine in the lab, and now we’re finally able to examine its potential in people. Hopefully this work will lead to a new treatment option for people with opioid use disorder and support a path to recovery,” said NCATS Director Joni Rutter, Ph.D.

    The trial is part of the Helping to End Addiction Long-term® Initiative, or NIH HEAL Initiative®

    NIH HEAL Initiative and Helping to End Addiction Long-term are registered service marks of the U.S. Department of Health and Human Services.

    About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

    NIH…Turning Discovery Into Health®

    Source: NIH

    Source: HealthDay

    More news resources

  • FDA Medwatch Drug Alerts
  • Daily MedNews
  • News for Health Professionals
  • New Drug Approvals
  • New Drug Applications
  • Clinical Trial Results
  • Generic Drug Approvals
  • Drugs.com Podcast

    • Subscribe to our newsletter

    Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

    Posted : 2026-06-02 17:15

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords